Insmed, Inc. $INSM Stock Holdings Reduced by Baker BROS. Advisors LP

Baker BROS. Advisors LP lowered its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 13.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,703,484 shares of the biopharmaceutical company’s stock after selling 1,009,416 shares during the quarter. Insmed makes up about 7.0% of Baker BROS. Advisors LP’s holdings, making the stock its 4th biggest position. Baker BROS. Advisors LP owned 3.14% of Insmed worth $965,369,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Stone House Investment Management LLC purchased a new position in shares of Insmed in the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. lifted its position in Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Insmed by 169.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 151 shares in the last quarter. Finally, RiverPark Advisors LLC acquired a new position in Insmed in the third quarter valued at $38,000.

Insider Activity at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the transaction, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. This trade represents a 67.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. This trade represents a 5.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 189,651 shares of company stock worth $31,784,545 over the last quarter. Company insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Stifel Nicolaus set a $205.00 target price on Insmed in a research report on Thursday, February 19th. Truist Financial set a $205.00 target price on Insmed in a research report on Monday, January 12th. HC Wainwright restated a “buy” rating and set a $230.00 price target on shares of Insmed in a research note on Monday, February 23rd. Citigroup reaffirmed an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Finally, Barclays began coverage on Insmed in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Insmed has an average rating of “Buy” and a consensus price target of $207.52.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $139.50 on Friday. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The stock has a market capitalization of $30.07 billion, a price-to-earnings ratio of -21.76 and a beta of 1.13. The company has a 50-day simple moving average of $155.18 and a 200-day simple moving average of $165.94. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The company had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business’s quarterly revenue was up 152.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) EPS. On average, analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.